A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers
Status:
Completed
Trial end date:
2018-08-09
Target enrollment:
Participant gender:
Summary
A Phase 1 study to assess the effect of itraconazole, a strong inhibitor of CYP3A and
P-glycoprotein, on the pharmacokinetics (PK) of orvepitant in healthy male volunteers.
Subjects will receive two single doses of 20mg orvepitant, once alone and once in combination
with repeat doses of itraconazole. All subjects will follow the same sequence - orvepitant
alone followed by orvepitant in combination with itraconazole.